(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/173740 A1

(51) International Patent Classification:
A61K 31/4985 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2021/019502

(22) International Filing Date:
25 February 2021 (25.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/982,872 28 February 2020 (28.02.2020) US
63/051,756 14 July 2020 (14.07.2020) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; 150 Clove Road, Overlook at Great Notch, Suite 8, Little Falls, New Jersey 07424 (US).

(72) Inventors: **GARREN, Hideki**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). **TENG, Edmond Huatung**; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US). **VIACCOZ, Aurelien**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **VON BUEDINGEN, Hans-Christian**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH).

(74) Agent: **MACKENZIE, Katherine, J.** et al.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/173740 A1

(54) Title: METHODS OF TREATING PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE

(57) Abstract: Provided herein are methods of treating Primary Progressive Multiple Sclerosis (PPMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.